Optimal first-line treatment in ovarian cancer

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Raja, F A ^a   Chopra, N ^b   Ledermann, J A ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Anti angiogenic agents; Dose dense; First line treatment; Intraperitoneal chemotherapy; Ovarian cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FARLETUZUMAB; FOLATE RECEPTOR 1; GANITUMAB; INSULIN GROWTH FACTOR 1; IRINOTECAN; LINSITINIB; NINTEDANIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; SOMATOMEDIN; SORAFENIB; SUNITINIB; TREBANANIB; UNCLASSIFIED DRUG; VINTAFOLIDE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; COMPARATIVE EFFECTIVENESS; DIARRHEA; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERTENSION; LIVER FUNCTION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RECURRENCE FREE SURVIVAL; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84866749053     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds315     Document Type: Article

References (67)

1. Ferlay J, Shin HR, Bray F et al. Cancer Incidence and Mortality Worldwide. In IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer 2010, 2008.
2. Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 2011; 305: 2295-2303.
3. Goff BA, Mandel L, Muntz HG et al. Ovarian carcinoma diagnosis. Cancer 2000; 89: 2068-2075.
4. Goff BA, Mandel LS, Drescher CW et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109: 221-227.
5. Hippisley-Cox J, Coupland C. Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm. BMJ 2012; 344: 8009.
6. Lim AW, Mesher D, Gentry-Maharaj A et al. Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes. J Natl Cancer Inst 2012; 104: 114-124.
7. Colombo N, Peiretti M, Parma G et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl. 5): v23-v30.
8. Morgan RJJ, Alvarez RD, Armstrong DK et al. NCCN clinical practice guidelines in oncology: epithelial ovarian cancer. J Natl Compr Cancer Netw 2011; 9: 82-113.
9. Ahmed FY, Wiltshaw E, A'Hern RP et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 2968-2975.
10. Vergote I, De Brabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357: 176-182.
11. Colombo N, Guthrie D, Chiari S et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003; 95: 125-132.
12. Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 2003; 95: 113-125.
13. Trimbos JB, Parmar M, Vergote I et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-112.
14. Swart AM, on behalf of ICON Collaborators. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). In Journal of Clinical Oncology. 2007 ASCO Annual Meeting Proceedings Part I 2007; 25(18S Suppl.): 5509.
15. Bell J, Brady MF, Young RC et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a gynecologic oncology group study. Gynecol Oncol 2006; 102: 432-439.
16. Mayer AR, Chambers SK, Graves E et al. Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol 1992; 47: 223-227.
17. Kurman RJ, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-443.
18. Braicu EI, Sehouli J, Richter R et al. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. Br J Cancer 2011; 105: 1818-1824.
19. Higashi M, Kajiyama H, Shibata K et al. Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types. Gynecol Oncol 2011; 123: 474-478.
20. Hess V, A'Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-1044.
21. Lee YY, Kim TJ, Kim MJ et al. Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol 2011; 122: 541-547.
22. Mackay HJ, Brady MF, Oza AM et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20: 945-952.
23. Anglesio MS, George J, Kulbe H et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011; 17: 2538-2548.
24. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
25. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2003; 21: 3194-3200.
26. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
27. Piccart MJ, Bertelsen K, Stuart G et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide- cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 2003; 13(Suppl. 2): 144-148.
28. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505-515.
29. Bookman MA, for the Gynecologic Cancer Inter Group through the Gynecologic Oncology G. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol (Meeting Abstracts) 2006; 24: 5002.
30. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel- carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-1691.
31. du Bois A, Rochon J, Pfisterer J et al. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol 2009; 112: 422-436.
32. Trope C, Kaern J. Primary surgery for ovarian cancer. Eur J Surg Oncol 2006; 32: 844-852.
33. Junor EJ, Hole DJ, McNulty L et al. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 1999; 106: 1130-1136.
34. Polterauer S, Vergote I, Concin N et al. Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA-IV: Analysis of the OVCAD Data. Int J Gynecol Cancer 2012; 22: 380-385.
35. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248-1259.
36. Stuart GC, Kitchener H, Bacon M et al. 2010 Gynecologic cancer Intergroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer 2011; 21: 750-755.
37. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological cancer cooperative group of the European organization for research and treatment of cancer. N Engl J Med 1995; 332: 629-634.
38. Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-953.
39. Vergote I, Trope CG, Amant F et al. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J Clin Oncol 2011; 29: 4076-4078.
40. Chi DS, Bristow RE, Armstrong DK et al. Is the easier way ever the better way? J Clin Oncol 2011; 29: 4073-4075.
41. Rauh-Hain JA, Rodriguez N, Growdon WB et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol 2012; 19: 959-965.
42. Kaye SB, Lewis CR, Paul J et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329-333.
43. Kaye SB, Paul J, Cassidy J et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 1996; 14: 2113-2119.
44. Mobus V, Wandt H, Frickhofen N et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007; 25: 4187-4193.
45. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-1955.
46. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwestern oncology group, and eastern cooperative oncology group. J Clin Oncol 2001; 19: 1001-1007.
47. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
48. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331-1338.
49. van der Burg ME, Boere IA, Berns PM. Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra. Ann Oncol 2011; 22(Suppl. 8): viii33-viii39.
50. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483.
51. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
52. Aghajanian C, Finkler NJ, Rutherford T et al. OCEANS: A randomized, doubleblinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011; 29(suppl); Abstr LBA5007.
53. Ledermann JA, Marth C, Carey MS et al. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer 2011; 21: 763-770.
54. Friedlander M, Hancock KC, Rischin D et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010; 119: 32-37.
55. Ledermann JA, Hackshaw A, Kaye S et al. Randomized phase II placebocontrolled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011; 29: 3798-3804.
56. Matulonis UA, Berlin S, Ivy P et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27: 5601-5606.
57. Biagi JJ, Oza AM, Chalchal HI et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC clinical trials group study. Ann Oncol 2011; 22: 335-340.
58. Matei D, Sill MW, Lankes HA et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011; 29: 69-75.
59. Karlan BY, Oza AM, Richardson GE et al. Randomized, double-blind, placebocontrolled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012; 30: 362-371.
60. Kohler M, Bauknecht T, Grimm M et al. Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas. Eur J Cancer 1992; 28A: 1432-1437.
61. Schilder RJ, Sill MW, Chen X et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a gynecologic oncology group study. Clin Cancer Res 2005; 11: 5539-5548.
62. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-8115.
63. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
64. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-861.
65. Ledermann JA, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum sensitive relapsed ovarian cancer. N Engl J Med 2012; 366(15): 1382-1392.
66. Konner JA, Bell-McGuinn KM, Sabbatini P et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010; 16: 5288-5295.
67. Naumann R, Symanowski J, Ghamande S et al. PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol 2010; 28(suppl); Abstr LBA5012b.